Olmesartan inhibits cardiac hypertrophy in mice overexpressing renin independently of blood pressure: Its beneficial effects on ace2/ang (1–7)/mas axis and nadph …

T Tanno, H Tomita, I Narita, T Kinjo… - Journal of …, 2016 - journals.lww.com
Enhanced renin–angiotensin activity causes hypertension and cardiac hypertrophy. The
angiotensin (Ang)-converting enzyme (ACE) 2/Ang (1–7)/Mas axis pathway functions …

The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms

CS McLachlan - Clinical Hypertension, 2020 - Springer
There is current debate concerning the use of angiotensin-converting enzyme (ACE)
inhibitors or angiotensin II type 1 receptor blockers (ARBs), for hypertension management …

[HTML][HTML] The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

Z Huang, J Cao, Y Yao, X Jin, Z Luo, Y Xue… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus
(designated as SARS-CoV-2) has become a pandemic worldwide. Based on the current …

Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients

D van Lier, M Kox, K Santos… - ERJ Open …, 2021 - Eur Respiratory Soc
Pharmacological blockade of the renin–angiotensin–aldosterone system (RAAS) with
angiotensin-converting enzyme (ACE)-inhibitors and angiotensin receptor blockers (ARBs) …

[HTML][HTML] Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review

B Singh, D Singh, V Verma, R Yadav… - Journal of Pharmaceutical …, 2022 - Elsevier
Abstract As of August 16, 2021, there have been 207,173,086 confirmed cases and
4,361,996 deaths due to the coronavirus disease (COVID-19), and the pandemic remains a …

Could anti‐hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID‐19 infection? data from centers of southern Italy

C Sardu, P Maggi, V Messina, P Iuliano… - Journal of the …, 2020 - Am Heart Assoc
BACKGROUND Coronavirus disease 2019 (COVID‐19) is the cause of a pandemic disease,
with severe acute respiratory syndrome by binding target epithelial lung cells through …

Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats

H Nishimatsu, E Suzuki, H Satonaka… - American Journal …, 2005 - journals.physiology.org
To study the mechanisms of vascular dysfunction in diabetes mellitus, we examined the
responses of the aorta to adrenomedullin (AM) and ANG II in obese Zucker (OZ), lean …

Cardioprotective effects of pitavastatin on cardiac performance and remodeling in failing rat hearts

N Kobayashi, H Takeshima… - American journal of …, 2009 - academic.oup.com
Background Activation of phosphatidylinositol 3-kinase (PI3K)-Akt signaling by statins
increases the activity of endothelial nitric oxide synthase (eNOS). We investigate whether …

Treatment options available for COVID-19 and an analysis on possible role of combination of rhACE2, angiotensin (1-7) and angiotensin (1-9) as effective therapeutic …

S Muslim, N Nasrin, FO Alotaibi, G Prasad… - SN comprehensive …, 2020 - Springer
Abstract Corona virus disease (COVID-19), caused by SARS-CoV-2, is rapidly spreading all
around the world and is posing a threat to mankind. Since SARS-CoV-2 is a novel virus, little …

Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers

G de Simone - Eur Soc Cardiol, 2020 - sigg.it
13 Mar 2020 Based on initial reports from China, and subsequent evidence that arterial
hypertension may be associated with increased risk of mortality in hospitalized COVID-19 …